# Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

> **NCT00137748** · PHASE2,PHASE3 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 50 (estimated)

## Conditions studied

- Hypogammaglobulinemia

## Interventions

- **DRUG:** CMV-Ig

## Key facts

- **NCT ID:** NCT00137748
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137748, "Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00137748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*